GlaxoSmithKline submitted a Biologics License Application to the U.S. FDA based upon results from the pivotal DREAMM-2 Phase III trial of belantamab mafodotin in multiple myeloma.

Mersana Therapeutics Inc. announced that the U.S. Food and Drug Administration lifted the partial clinical hold on the Phase 1 study of the experimental cancer drug XMT-1522.